GlassScriptPhysician profile
Robert Fontanilla
NPI 1184005258
$31,829.48
in general payments reported to CMS, 2019-2025
16 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,385 · 2022: $3,544 · 2024: $977 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $4,773 · Travel and Lodging: $2,230 · Consulting Fee: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,097.50 |
| Food and Beverage | $4,773.26 |
| Travel and Lodging | $2,229.85 |
| Consulting Fee | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19,697.92 | 2021-2025 | Yeztugo, Descovy, Biktarvy |
| Abbvie INC. | $7,573.35 | 2021-2025 | |
| Viiv Healthcare Company | $3,252.75 | 2021-2025 | Apretude, Cabenuva, Dovato |
| Antares Pharma, INC. | $528.68 | 2021-2025 | Xyosted |
| Esperion Therapeutics, INC. | $162.64 | 2021 | |
| Lilly USA, LLC | $120.80 | 2024 | Olumiant |
| Novo Nordisk INC | $112.00 | 2021-2025 | Wegovy |
| Janssen Products, LP | $98.87 | 2022 | |
| Janssen Biotech, INC. | $77.48 | 2021-2022 | |
| Amarin Pharma, INC. | $54.48 | 2021 | |
| Merck Sharp & Dohme LLC | $51.01 | 2025 | Pifeltro, Isentress, Delstrigo |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Tolmar, INC. | $22.18 | 2025 | Jatenzo |
| Theratechnologies INC. | $20.00 | 2022 | |
| Napo Pharmaceuticals INC | $17.01 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fontanilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.